Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

TissueGen: drug-eluting fiber platform spun out of UT Southwestern and UT Arlington bioengineering

7 October 2026 · By · Wire by Fusion42

Published

7 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at app.dealroom.co →

◆ Verified

Fusion42 · 7 October 2026 · Fusion42 review

TissueGen, a spin-out from UT Southwestern and UT Arlington, develops biodegradable polymer fibers under the ELUTE fiber platform that release drugs and biologics for applications in nerve regeneration, orthopedic soft-tissue repair, and wound care.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You are now facing a drug delivery platform that bridges implantable and topical applications with biodegradable fibers, opening new routes for medical product innovation. This tech demands fresh clinical partnerships and product exploration this quarter.

◆ Coverage

1 source · 7 Oct 2026

◆ Related on Wire

◆ Topics

Medtechdrug-deliverybiodegradable-fibersmedtechimplantablewound-care